Phreesia, Inc. (PHR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Phreesia, Inc. (PHR) trades at $10.72 with AI Score 55/100 (Grade B). Phreesia, Inc. offers a SaaS-based platform for the healthcare industry, streamlining patient intake and payment processes. Market cap: $663M, Sector: Healthcare.
Price as of Jul 12, 2026 · Last analyzed: May 9, 2026PHR stock analysis for 2026: Analysts have set a consensus price target of $26.50 for Phreesia, Inc., suggesting 147.2% upside from the current price of $10.72. The AI MoonshotScore is 55/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
PHR: 1/3 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Phreesia, Inc. (PHR) Healthcare & Pipeline Overview
Phreesia, Inc. delivers an integrated SaaS platform for healthcare, optimizing patient intake, payments, and engagement. Its diverse solutions, including mobile and kiosk options, cater to healthcare providers and life sciences companies, positioning it as a key player in healthcare information services across the US and Canada.
What Is the Investment Thesis for PHR?
Phreesia, Inc. presents a compelling investment case driven by its integrated SaaS platform that addresses critical needs in the healthcare industry. With a gross margin of 61.3%, the company demonstrates a strong ability to maintain profitability while scaling its operations. Key growth catalysts include expanding its platform to new healthcare segments and increasing adoption among existing clients. The company's revenue cycle solutions and access solutions are particularly well-positioned to capitalize on the growing demand for efficient patient management systems. However, investors should be aware of the potential risks associated with competition and evolving healthcare regulations. The company's P/E ratio stands at 62.1, which may indicate it's trading at a premium.
Based on FMP financials and quantitative analysis
PHR Key Highlights
- Market capitalization of $663M indicates moderate size within the healthcare information services sector.
- P/E ratio of 62.1 suggests investors have high expectations for future earnings growth.
- Gross margin of 61.3% reflects strong pricing power and efficient cost management.
- Profit margin of 0.5% indicates room for improvement in operational efficiency and cost control.
- Beta of 0.85 suggests the stock is less volatile than the overall market.
Who Are PHR's Competitors?
PHR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACCD Accolade, Inc. | $7.02 | +0.00% | $576M | 55 |
| RSLBF RaySearch Laboratories AB (publ) | $24.00 | +13.37% | $814M | 57 |
| HSTM HealthStream, Inc. | $28.08 | +0.21% | $820M | 87 |
| NRC National Research Corporation | $21.65 | -0.28% | $488M | 69 |
| KSIOF Kneat.com, Inc. | $4.56 | +0.00% | $438M | 63 |
| NUTX Nutex Health, Inc. | $183.91 | +0.30% | $1.10B | 94 |
| SLGCW SomaLogic, Inc. | $0.09 | -28.33% | $396M | 55 |
| SLGC SomaLogic, Inc. | $2.10 | -4.55% | $396M | 55 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PHR's Key Strengths?
- Integrated SaaS platform with comprehensive solutions.
- Diverse deployment modalities (mobile, tablets, kiosks).
- Strong focus on patient intake and payment processing.
- Established presence in the US and Canada.
What Are PHR's Weaknesses?
- Relatively low profit margin of 0.5%.
- High P/E ratio may indicate overvaluation.
- Dependence on the healthcare industry and regulatory environment.
- Limited geographic diversification.
What Could Drive PHR Stock Higher?
- Expansion of Phreesia's platform into new healthcare segments, such as behavioral health and telehealth, to address evolving patient needs and market demands.
- Increased adoption of Phreesia's revenue cycle management solutions by healthcare providers seeking to improve billing accuracy and reduce administrative costs.
- Strategic partnerships with pharmaceutical companies to deliver targeted marketing and patient education programs, driving revenue growth and enhancing platform value.
- Launch of new data analytics capabilities to provide healthcare providers with actionable insights for improving patient outcomes and operational efficiency.
- Continued innovation in patient engagement tools to enhance communication and adherence, leading to better health outcomes and increased patient satisfaction.
What Are the Key Risks for PHR?
- Financial-distress signal — its Altman Z-Score of 0.61 sits in the distress zone (elevated bankruptcy risk).
- Rich valuation — a P/E of 62.1 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Increased competition from established healthcare IT vendors and emerging startups, potentially impacting market share and pricing power.
- Evolving healthcare regulations and compliance requirements, such as HIPAA and data privacy laws, could increase operational costs and create legal liabilities.
- Cybersecurity threats and data breaches could compromise patient information and damage the company's reputation.
- Economic downturn and reduced healthcare spending could negatively impact demand for Phreesia's solutions.
- Dependence on third-party vendors and service providers could create supply chain disruptions and operational challenges.
What Are the Growth Opportunities for PHR?
- Expansion into new therapeutic areas represents a significant growth opportunity for Phreesia. By tailoring its platform to meet the specific needs of various medical specialties, such as oncology or cardiology, Phreesia can attract new clients and increase its market share. The market for specialized healthcare IT solutions is estimated to reach $30 billion by 2028, presenting a substantial opportunity for Phreesia to expand its offerings and capture a larger share of this growing market. Timeline: Ongoing.
- Increasing adoption of Phreesia's platform among existing clients is another key growth driver. By offering additional modules and features, such as advanced analytics and patient engagement tools, Phreesia can encourage its current clients to expand their usage of the platform. The market for patient engagement solutions is projected to reach $15 billion by 2027, highlighting the potential for Phreesia to drive revenue growth through increased adoption among its existing customer base. Timeline: Ongoing.
- Strategic partnerships with pharmaceutical, medical device, and biotechnology companies offer a valuable avenue for growth. By collaborating with these companies to deliver targeted marketing content and clinical support to patients, Phreesia can generate new revenue streams and enhance its platform's value proposition. The market for healthcare marketing and advertising is estimated to reach $45 billion by 2026, presenting a significant opportunity for Phreesia to leverage its platform to connect with patients and drive growth. Timeline: Ongoing.
- Geographic expansion into new markets, particularly in Europe and Asia, represents a long-term growth opportunity for Phreesia. By adapting its platform to meet the regulatory and cultural requirements of these markets, Phreesia can tap into new sources of revenue and diversify its geographic footprint. The global healthcare IT market is projected to reach $400 billion by 2028, highlighting the potential for Phreesia to expand its international presence and capitalize on the growing demand for digital health solutions worldwide. Timeline: 3-5 years.
- Leveraging data analytics to improve patient outcomes and drive cost savings presents a compelling growth opportunity. By analyzing the vast amounts of data collected through its platform, Phreesia can identify trends, predict patient needs, and develop targeted interventions to improve healthcare delivery. The market for healthcare analytics is estimated to reach $35 billion by 2027, underscoring the potential for Phreesia to leverage its data assets to create new value for its clients and drive growth. Timeline: Ongoing.
What Opportunities Does PHR Have?
- Expansion into new therapeutic areas and healthcare segments.
- Increased adoption of platform among existing clients.
- Strategic partnerships with pharmaceutical and medical device companies.
- Geographic expansion into new international markets.
What Threats Does PHR Face?
- Intense competition from other healthcare IT providers.
- Evolving healthcare regulations and compliance requirements.
- Potential cybersecurity threats and data breaches.
- Economic downturn and reduced healthcare spending.
What Are PHR's Competitive Advantages?
- Integrated platform offering a comprehensive suite of solutions.
- Established relationships with a wide range of healthcare providers.
- Proprietary technology and data analytics capabilities.
- Strong brand reputation and market presence in the healthcare IT industry.
What Does PHR Do?
Phreesia, Inc., established in 2005 and headquartered in Raleigh, North Carolina, provides a comprehensive SaaS-based software and payment platform tailored for the healthcare industry in the United States and Canada. The company's core offering, the Phreesia Platform, is a suite of solutions designed to streamline and manage the patient intake process, while also providing an integrated payments solution for processing patient payments. The platform is deployed through various modalities, including Phreesia Mobile (patients' mobile devices), Phreesia Dashboard (a web-based dashboard for healthcare clients), PhreesiaPads (self-service intake tablets), and Arrivals Kiosks (on-site kiosks). The Phreesia Platform includes a registration solution automating patient self-registration, a revenue cycle solution providing insurance verification, point-of-sale payments applications, and cost estimation tools. It also offers access solutions featuring an appointment scheduling system for online appointments, reminders, and referral tracking. Furthermore, the platform extends to life sciences, delivering targeted and clinically relevant marketing content to patients. Phreesia's clinical support solution collects clinical intake and patient-reported outcome (PRO) data for approximately 25 specialties, enabling healthcare clients to communicate with patients through surveys, announcements, text and email messaging, and health campaigns. The company also provides COVID-19 support modules for managing vaccine delivery, identifying vaccine-hesitant patients, screening for COVID-19 risk factors, enabling contactless check-in, and collecting intake information during telehealth visits. Phreesia serves a diverse clientele, including individual patients, single-specialty practices, multi-specialty groups, health systems, and pharmaceutical, medical device, and biotechnology companies.
What Products and Services Does PHR Offer?
- Provides a SaaS-based software platform for the healthcare industry.
- Offers solutions for managing the patient intake process.
- Provides integrated payment solutions for patient payments.
- Deploys its platform through mobile devices, web dashboards, self-service tablets, and on-site kiosks.
- Automates patient self-registration.
- Offers insurance verification and cost estimation tools.
- Delivers targeted marketing content to patients through its life sciences solution.
- Collects clinical intake and patient-reported outcome data.
How Does PHR Make Money?
- Generates revenue through subscription fees for its SaaS platform.
- Earns revenue from processing patient payments.
- Partners with pharmaceutical and medical device companies for targeted marketing campaigns.
- Offers various modules and features to healthcare providers, driving adoption and revenue.
What Industry Does PHR Operate In?
Phreesia operates within the rapidly evolving healthcare information services industry, which is experiencing significant growth due to increasing demand for digital health solutions and the need for streamlined patient management. The industry is characterized by intense competition, with companies vying to offer comprehensive platforms that integrate patient intake, payments, and clinical support. Phreesia's SaaS-based model and focus on providing integrated solutions position it favorably within this landscape, allowing it to capitalize on the growing trend towards digital transformation in healthcare. As healthcare providers increasingly adopt technology to improve efficiency and patient experience, companies like Phreesia are poised to benefit from the expanding market.
Who Are PHR's Key Customers?
- Single-specialty practices
- Multi-specialty groups
- Health systems
- Pharmaceutical companies
- Medical device companies
Company Profile
Phreesia, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Wilmington, US. The company is led by CEO Chaim Indig. PHR has traded publicly since 2019.
How Phreesia, Inc. Is Valued
Phreesia, Inc. carries a market capitalization of $663M, placing it in the small-cap category. Relative to its peer group, PHR's quantitative score of 55/100 is below the peer average of 66/100.
ROE 3%Key Financial Metrics
Return on equity for Phreesia, Inc. stands at 2.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.4%, showing how much profit it generates from its asset base. PHR trades at a trailing price-to-earnings ratio of 62.05, above the Healthcare sector average of ~23x. Its free cash flow yield is 11.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Phreesia, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.61 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Phreesia, Inc. revenue of about $480.2M for fiscal 2026, with EPS near $0.08. The estimate reflects 12 contributing analysts.
Net buyingInsider Activity
Over the past six months, Phreesia, Inc. insiders filed 30 SEC Form 4 transactions — 18 sales and 12 purchases. On net that is roughly 79K shares acquired (about $563K) — insiders putting money in tends to read as conviction.
PHR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Integrated SaaS platform with comprehensive solutions.
- Diverse deployment modalities (mobile, tablets, kiosks).
- Strong focus on patient intake and payment processing.
- Established presence in the US and Canada.
Bear Case
- Relatively low profit margin of 0.5%.
- High P/E ratio may indicate overvaluation.
- Dependence on the healthcare industry and regulatory environment.
- Limited geographic diversification.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
PHR Latest News
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Phreesia, Inc. of Class Action Lawsuit and Upcoming Deadlines – PHR
globenewswire.com · Jun 30, 2026
-
Phreesia, Inc. Class Action Reminder - Robbins LLP Encourages PHR Investors to Contact the Firm for Information About Their Rights
businesswire.com · Jun 23, 2026
-
PHREESIA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHR
newsfilecorp.com · Jun 23, 2026
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Phreesia, Inc. of Class Action Lawsuit and Upcoming Deadlines – PHR
globenewswire.com · Jun 23, 2026
PHR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PHR.
Price Targets
Consensus target: $26.50
PHR MoonshotScore
What does this score mean?
The MoonshotScore rates PHR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Phreesia, Inc. of Class Action Lawsuit and Upcoming Deadlines – PHR
Phreesia, Inc. Class Action Reminder - Robbins LLP Encourages PHR Investors to Contact the Firm for Information About Their Rights
PHREESIA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PHR
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Phreesia, Inc. of Class Action Lawsuit and Upcoming Deadlines – PHR
Latest Phreesia, Inc. Analysis
Leadership: Chaim Indig
CEO
Chaim Indig is the Chief Executive Officer of Phreesia, Inc. His professional background and educational details were not provided in the source data. As CEO, he is responsible for leading the company's strategic direction and overseeing its day-to-day operations. His leadership is crucial in guiding Phreesia's growth and innovation within the healthcare technology sector. He manages a workforce of 2082 employees.
Track Record: Information regarding Chaim Indig's specific achievements, strategic decisions, and company milestones during his tenure as CEO was not available in the provided data. Therefore, a comprehensive assessment of his track record cannot be provided.
PHR Healthcare Stock FAQ
What does the AI Score mean for PHR?
PHR holds an AI Score of 55/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Phreesia, Inc. offers a SaaS-based platform for the healthcare industry, streamlining patient intake and payment processes. The company's solutions cater to various healthcare providers and life …
What does Phreesia, Inc. do?
Phreesia, Inc. provides a SaaS-based platform for the healthcare industry, streamlining patient intake, payment processing, and patient engagement. Its integrated solutions cater to various healthcare providers, including single-specialty practices, multi-specialty groups, and health systems, as well as pharmaceutical, medical device, and biotechnology companies.
What are the main risks for PHR?
Phreesia faces several key risks, including intense competition in the healthcare IT market, evolving healthcare regulations and compliance requirements, and potential cybersecurity threats. Increased competition could impact market share and pricing power, while regulatory changes may increase operational costs. Cybersecurity breaches could compromise patient data and damage the company's reputation. Additionally, economic downturns and reduced healthcare spending could negatively affect demand for Phreesia's solutions.
How does Phreesia, Inc. navigate regulatory approval processes?
Information regarding Phreesia, Inc.'s specific regulatory approval processes, FDA/EMA track record, pending approvals, and compliance strategy was not available in the provided data. Therefore, a comprehensive assessment of how Phreesia navigates regulatory hurdles cannot be provided. Investors should consult the company's SEC filings and investor relations materials for more information on this topic.
What are the key growth opportunities for PHR in healthcare?
Phreesia's key growth opportunities in healthcare include expanding its platform into new therapeutic areas, increasing adoption among existing clients, and forming strategic partnerships with pharmaceutical and medical device companies. By tailoring its solutions to meet the specific needs of various medical specialties, Phreesia can attract new clients and increase its market share.
What are the key factors to evaluate for PHR?
Phreesia, Inc. (PHR) holds an AI score of 55/100 (moderate). P/E: 62.1x vs the S&P 500's ~20-25x. Analysts target $26.50 (+147%). Not financial advice.
How frequently does PHR data refresh on this page?
PHR's price was last updated on Jul 12, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PHR's recent stock price performance?
Phreesia, Inc. (PHR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated SaaS platform with comprehensive solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PHR overvalued or undervalued right now?
Phreesia, Inc. (PHR) trades at 62.1x earnings. Analysts target $26.50 (+147%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on the provided source data.
- Analyst opinions and forward-looking statements are not included due to data limitations.
- CEO track record and tenure data are incomplete.